{"id":42774,"date":"2019-05-01T12:40:31","date_gmt":"2019-05-01T10:40:31","guid":{"rendered":"https:\/\/newserver.fyb.de\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/"},"modified":"2019-05-01T12:40:31","modified_gmt":"2019-05-01T10:40:31","slug":"series-a-financing-alentis-therapeutics-receives-chf-12-5-million","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/","title":{"rendered":"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million"},"content":{"rendered":"<p>Basel \u2014 <strong>ALENTIS Thera\u00adpeu\u00adtics<\/strong> (\u201cALENTIS\u201d), a Swiss-French biotech company is deve\u00adlo\u00adping new, inno\u00adva\u00adtive drugs for the treat\u00adment of advan\u00adced liver dise\u00ada\u00adses and cancer. In a CHF 12.5 million (\u20ac11.1 million; USD 12.5 million) Series A finan\u00adcing, Swiss venture capi\u00adtal firms <strong>BioMed\u00adPart\u00adners<\/strong> and <strong>BB Pureos Bioven\u00adtures<\/strong> led the consor\u00adtium, which was joined by <strong>BPI France, Schro\u00adder Adveq <\/strong>and the <strong>German High Tech Gr\u00fcn\u00adder\u00adfonds (HTGF)<\/strong>.<\/p>\n<p><strong>Dr. Markus L.E.Ewert<\/strong>, MBA has been appoin\u00adted CEO of the new company. He was previously a board member at Ablynx and contri\u00adbu\u00adted to one of the largest U.S. biotech IPOs of the year and the very successful sale of Ablynx to Sanofi. Previously, Dr. Ewert led global corpo\u00adrate deve\u00adlo\u00adp\u00adment at GE Health\u00adcare, held leader\u00adship posi\u00adti\u00adons at Novar\u00adtis, and successfully built life science compa\u00adnies based on innovation.<\/p>\n<p>ALENTIS\u2019 most advan\u00adced project is a huma\u00adni\u00adzed mono\u00adclonal anti\u00adbody against a protein that plays a key role in the patho\u00adlogy of liver fibro\u00adsis and hepa\u00adto\u00adcel\u00adlu\u00adlar carci\u00adnoma. Limi\u00adted thera\u00adpeu\u00adtic opti\u00adons are available for the treat\u00adment of advan\u00adced liver dise\u00adase and cancer. Alen\u00adtis\u2019 inno\u00adva\u00adtive project aims to address this major clini\u00adcal problem.<\/p>\n<p>ALENTIS rese\u00adarch is based on an inno\u00adva\u00adtive tech\u00adno\u00adlogy plat\u00adform that uses a gene expres\u00adsion signa\u00adture that diffe\u00adren\u00adtia\u00adtes between good and poor progno\u00adsis in liver dise\u00adase. This plat\u00adform can be used to find and deve\u00adlop further drug candi\u00adda\u00adtes for the treat\u00adment of advan\u00adced liver dise\u00ada\u00adses and cancer.<\/p>\n<p>ALENTIS is based on ground\u00adbrea\u00adking rese\u00adarch conduc\u00adted by Prof. Dr. Thomas Baumer\u00adt\u2019s labo\u00adra\u00adtory at the Univer\u00adsity of Stras\u00adbourg, the Inserm Insti\u00adtute for Viral and Liver Dise\u00adase, the Labo\u00adra\u00adtory of Excel\u00adlence HepSYS and the Insti\u00adtut Hospi\u00adtal-Univer\u00adsi\u00adtaire Stras\u00adbourg, and other colla\u00adbo\u00adra\u00adtors, inclu\u00adding Prof. Dr. Yujin Hoshida at the Univer\u00adsity of Texas Southwes\u00adtern in Dallas. SATT Conec\u00adtus, the tech\u00adno\u00adlogy trans\u00adfer support orga\u00adniza\u00adtion in Alsace (France), was instru\u00admen\u00adtal in provi\u00adding, buil\u00adding and secu\u00adring the patent port\u00adfo\u00adlio licen\u00adsed to ALENTIS. BaseLaunch, an inno\u00adva\u00adtion acce\u00adle\u00adra\u00adtor opera\u00adted by BaselArea.swiss, was instru\u00admen\u00adtal in the early stages of the company\u2019s crea\u00adtion as a finan\u00adcial and opera\u00adtio\u00adnal supporter. Through this tri-natio\u00adnal colla\u00adbo\u00adra\u00adtion, ALENTIS is now head\u00adquar\u00adte\u00adred in Basel, Switz\u00ader\u00adland with a subsi\u00addiary in Stras\u00adbourg, France and a branch office in Germany.<\/p>\n<p>Thomas F. Baumert, M.D., Profes\u00adsor of Medi\u00adcine, Head of the Inserm Rese\u00adarch Insti\u00adtute and Chair of Hepa\u00adto\u00adlogy at the Univer\u00adsity Hospi\u00adtal of Stras\u00adbourg, and prin\u00adci\u00adpal foun\u00adder of ALENTIS, said, \u201cToge\u00adther with my colle\u00adagues, we are exci\u00adted to bring our new thera\u00adpeu\u00adtic approa\u00adches with their inno\u00adva\u00adtive and promi\u00adsing mecha\u00adnism of action into the clinic. Our goal is to improve the treat\u00adment of pati\u00adents with advan\u00adced liver disease.\u201d<\/p>\n<p>Dr. Andreas Walln\u00f6fer, former Head of Clini\u00adcal Rese\u00adarch &amp; Early Deve\u00adlo\u00adp\u00adment at F. Hoff\u00admann-La Roche Ltd. and now Gene\u00adral Part\u00adner at the Basel-based venture capi\u00adtal firm BioMed\u00adPart\u00adners, added: \u201cThe precli\u00adni\u00adcal data set of the ALENTIS lead program is very compre\u00adhen\u00adsive and convin\u00adcing. They demons\u00adtrate the thera\u00adpeu\u00adtic poten\u00adtial of the new phar\u00adma\u00adco\u00adlo\u00adgi\u00adcal approach in the treat\u00adment of advan\u00adced liver dise\u00ada\u00adses of diffe\u00adrent patho\u00adge\u00adne\u00adsis. Prof. Baumer\u00adt\u2019s rese\u00adarch is trans\u00adla\u00adtio\u00adnal and links rese\u00adarch and clinic through a progno\u00adstic gene expres\u00adsion signa\u00adture. This is extre\u00admely valuable for the opti\u00admal charac\u00adte\u00adriza\u00adtion and deve\u00adlo\u00adp\u00adment of the most advan\u00adced project and for the disco\u00advery of further programs for the treat\u00adment of liver diseases.\u201d<\/p>\n<p>The Board of Direc\u00adtors of ALENTIS will be compo\u00adsed of Neil Golds\u00admith, Co-Foun\u00adder and Chair\u00adman; Andreas Walln\u00f6fer, Gene\u00adral Part\u00adner at BioMed\u00adPart\u00adners; Martin M\u00fcnch\u00adbach, Mana\u00adging Part\u00adner at BB Pureos Bioven\u00adtures; Benoit Barteau, Senior Invest\u00adment Mana\u00adger at BPI France, and Prof. Thomas F.Baumert, Prin\u00adci\u00adpal Founder<\/p>\n<p><strong>About ALENTIS Therapeutics<\/strong><br>\nALENTIS Thera\u00adpeu\u00adtics (ALENTIS) disco\u00advers and deve\u00adlops inno\u00adva\u00adtive drugs for the treat\u00adment of advan\u00adced liver dise\u00ada\u00adses such as liver fibro\u00adsis, cirrho\u00adsis and liver cancer (hepa\u00adto\u00adcel\u00adlu\u00adlar carci\u00adnoma, HCC). \u2014 The Swiss-French biotech company, estab\u00adlished as ALENTIS Thera\u00adpeu\u00adtics AG in March 2019, is head\u00adquar\u00adte\u00adred in Basel, Switz\u00ader\u00adland, with a subsi\u00addiary in Stras\u00adbourg, France, and a branch office in Germany.<\/p>\n<p>ALENTIS has licen\u00adsed plat\u00adform tech\u00adno\u00adlo\u00adgies and mono\u00adclonal anti\u00adbo\u00addies that are the result of more than a decade of rese\u00adarch by the Univer\u00adsity of Stras\u00adbourg and Inserm, the French Natio\u00adnal Insti\u00adtute of Health and Mount Sinai Hospi\u00adtal, New&nbsp;York.<\/p>\n<p>Priva\u00adtely held ALENTIS is funded by leading venture inves\u00adtors BioMed\u00adPart\u00adners, BB Pureos Bioven\u00adtures, BPI France, Schro\u00adder Adveq and the German High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Basel \u2014 ALENTIS Thera\u00adpeu\u00adtics (\u201cALENTIS\u201d), a Swiss-French biotech company is deve\u00adlo\u00adping new, inno\u00adva\u00adtive drugs for the treat\u00adment of advan\u00adced liver dise\u00ada\u00adses and cancer. In a CHF 12.5 million (\u20ac11.1 million; USD 12.5 million) Series A finan\u00adcing, Swiss venture capi\u00adtal firms BioMed\u00adPart\u00adners and BB Pureos Bioven\u00adtures led the consor\u00adtium, which was joined by BPI France, Schroder&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42788,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-42774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-venture-capital-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Series A financing: ALENTIS Therapeutics receives CHF 12.5 million - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Basel \u2014 ALENTIS Thera\u00adpeu\u00adtics (\u201cALENTIS\u201d), a Swiss-French biotech company is deve\u00adlo\u00adping new, inno\u00adva\u00adtive drugs for the treat\u00adment of advan\u00adced liver dise\u00ada\u00adses and cancer. In a CHF 12.5 million (\u20ac11.1 million; USD 12.5 million) Series A finan\u00adcing, Swiss venture capi\u00adtal firms BioMed\u00adPart\u00adners and BB Pureos Bioven\u00adtures led the consor\u00adtium, which was joined by BPI France, Schro\u00adder [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-01T10:40:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1400\" \/>\n\t<meta property=\"og:image:height\" content=\"390\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million\",\"datePublished\":\"2019-05-01T10:40:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/\"},\"wordCount\":699,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/\",\"url\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/\",\"name\":\"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg\",\"datePublished\":\"2019-05-01T10:40:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg\",\"width\":1400,\"height\":390},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/","og_locale":"en_US","og_type":"article","og_title":"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million - FYB Financial Yearbook","og_description":"Basel \u2014 ALENTIS Thera\u00adpeu\u00adtics (\u201cALENTIS\u201d), a Swiss-French biotech company is deve\u00adlo\u00adping new, inno\u00adva\u00adtive drugs for the treat\u00adment of advan\u00adced liver dise\u00ada\u00adses and cancer. In a CHF 12.5 million (\u20ac11.1 million; USD 12.5 million) Series A finan\u00adcing, Swiss venture capi\u00adtal firms BioMed\u00adPart\u00adners and BB Pureos Bioven\u00adtures led the consor\u00adtium, which was joined by BPI France, Schro\u00adder [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2019-05-01T10:40:31+00:00","og_image":[{"width":1400,"height":390,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million","datePublished":"2019-05-01T10:40:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/"},"wordCount":699,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/","url":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/","name":"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg","datePublished":"2019-05-01T10:40:31+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/05\/a-csm_ventures_blutkoerper_c407244ddb.jpg","width":1400,"height":390},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/series-a-financing-alentis-therapeutics-receives-chf-12-5-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Series A financing: ALENTIS Therapeutics receives CHF 12.5 million"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42774"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42774\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42788"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}